西妥昔单抗联合XELOX对结直肠癌脑转移有疗效:1例报告。

Q1 Medicine CNS Oncology Pub Date : 2023-06-01 DOI:10.2217/cns-2023-0004
Ahmad Kh Ibrahimi, Maysa Al-Hussaini, Dima Abu Laban, Rula Ammarin, Lina Wehbeh, Abdelatif Al-Mousa
{"title":"西妥昔单抗联合XELOX对结直肠癌脑转移有疗效:1例报告。","authors":"Ahmad Kh Ibrahimi,&nbsp;Maysa Al-Hussaini,&nbsp;Dima Abu Laban,&nbsp;Rula Ammarin,&nbsp;Lina Wehbeh,&nbsp;Abdelatif Al-Mousa","doi":"10.2217/cns-2023-0004","DOIUrl":null,"url":null,"abstract":"<p><p>Brain metastasis (BM) from colorectal cancer (CRC) is rare and associated with poor prognosis. The mainstay of treatment for BM from CRC is radiotherapy, systemic treatment options for CRC can include novel targeted agents, conventional chemotherapy or a combination of both. Nevertheless, the efficacy of these systemic treatment options against BM from CRC is not yet fully established. Cetuximab, a monoclonal antibody, has been shown to be effective in patients with <i>KRAS</i> wild-type metastatic CRC. The combination of cetuximab with oxaliplatin-based chemotherapy is commonly utilized as a systemic treatment for metastatic CRC. Hereby, we report a case of BM from CRC with significant response after capecitabine and oxaliplatin (XELOX) combined with cetuximab.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"12 2","pages":"CNS97"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/18/be/cns-12-97.PMC10171034.pdf","citationCount":"0","resultStr":"{\"title\":\"Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report.\",\"authors\":\"Ahmad Kh Ibrahimi,&nbsp;Maysa Al-Hussaini,&nbsp;Dima Abu Laban,&nbsp;Rula Ammarin,&nbsp;Lina Wehbeh,&nbsp;Abdelatif Al-Mousa\",\"doi\":\"10.2217/cns-2023-0004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Brain metastasis (BM) from colorectal cancer (CRC) is rare and associated with poor prognosis. The mainstay of treatment for BM from CRC is radiotherapy, systemic treatment options for CRC can include novel targeted agents, conventional chemotherapy or a combination of both. Nevertheless, the efficacy of these systemic treatment options against BM from CRC is not yet fully established. Cetuximab, a monoclonal antibody, has been shown to be effective in patients with <i>KRAS</i> wild-type metastatic CRC. The combination of cetuximab with oxaliplatin-based chemotherapy is commonly utilized as a systemic treatment for metastatic CRC. Hereby, we report a case of BM from CRC with significant response after capecitabine and oxaliplatin (XELOX) combined with cetuximab.</p>\",\"PeriodicalId\":10469,\"journal\":{\"name\":\"CNS Oncology\",\"volume\":\"12 2\",\"pages\":\"CNS97\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/18/be/cns-12-97.PMC10171034.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CNS Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/cns-2023-0004\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/cns-2023-0004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

结直肠癌(CRC)的脑转移(BM)罕见且预后差。结直肠癌BM的主要治疗方法是放疗,结直肠癌的全身治疗选择包括新型靶向药物、常规化疗或两者结合。然而,这些系统治疗方案对结直肠癌BM的疗效尚未完全确定。西妥昔单抗是一种单克隆抗体,已被证明对KRAS野生型转移性结直肠癌患者有效。西妥昔单抗联合奥沙利铂为基础的化疗通常用于转移性结直肠癌的全身治疗。在此,我们报告一例卡培他滨和奥沙利铂(XELOX)联合西妥昔单抗治疗后显著缓解的结直肠癌BM病例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report.

Brain metastasis (BM) from colorectal cancer (CRC) is rare and associated with poor prognosis. The mainstay of treatment for BM from CRC is radiotherapy, systemic treatment options for CRC can include novel targeted agents, conventional chemotherapy or a combination of both. Nevertheless, the efficacy of these systemic treatment options against BM from CRC is not yet fully established. Cetuximab, a monoclonal antibody, has been shown to be effective in patients with KRAS wild-type metastatic CRC. The combination of cetuximab with oxaliplatin-based chemotherapy is commonly utilized as a systemic treatment for metastatic CRC. Hereby, we report a case of BM from CRC with significant response after capecitabine and oxaliplatin (XELOX) combined with cetuximab.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CNS Oncology
CNS Oncology Medicine-Neurology (clinical)
CiteScore
3.80
自引率
0.00%
发文量
12
审稿时长
13 weeks
期刊最新文献
Novel insights toward diagnosis and treatment of glioneuronal and neuronal tumors in young adults. Autologous stem cell transplantation in adults with atypical teratoid rhabdoid tumor: a case report and review. Neurofilament light chain in serum of cancer patients with acute neurological complications. Development of brain metastases in non-small-cell lung cancer: high-risk features. The challenges and clinical landscape of glioblastoma immunotherapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1